A 52-year-old woman with newly diagnosed ovarian cancer is being counseled about chemotherapy options. Regarding alkylating agents and their adverse effects, all of the following are true EXCEPT:

Explanation

## Alkylating Agents: Adverse Effects and Toxicities ### Correct Statements (True — NOT the answer) **Option A: Ifosfamide Encephalopathy and Mesna** - Ifosfamide causes **CNS toxicity** (encephalopathy, confusion, hallucinations, seizures) in 10–15% of patients - This is caused by accumulation of **chloroacetaldehyde**, a toxic metabolite - **Mesna does NOT prevent ifosfamide encephalopathy** — mesna only protects against hemorrhagic cystitis by binding acrolein/chloroacetaldehyde in the bladder - The statement in Option A is **FALSE** (mesna does not reverse encephalopathy), making it a candidate for the EXCEPT answer — however, see below for the stronger factual error **Option C: Cyclophosphamide and Hemorrhagic Cystitis** - Cyclophosphamide is metabolized to **acrolein**, a toxic metabolite excreted in urine - Acrolein causes direct bladder epithelial damage → hemorrhagic cystitis - Prevention: adequate hydration (dilutes urine) and **mesna** (binds acrolein in the bladder) - [cite: Harrison 21e Ch 96; KD Tripathi Ch 65] — **TRUE** **Option D: Melphalan Toxicity** - Melphalan's primary dose-limiting toxicity is **myelosuppression** (bone marrow suppression), not mucositis/GI toxicity - At high doses (used in stem cell transplantation), GI toxicity can occur, but it is NOT the primary dose-limiting toxicity - This statement is partially misleading but is a weaker distractor ### Incorrect Statement (The Answer — EXCEPT) **Option B: Platinum Compounds as Alkylating Agents** - Platinum compounds (cisplatin, carboplatin, oxaliplatin) are **NOT** classified as classical alkylating agents - They are classified as **platinum-based antineoplastic agents** (or platinum coordination complexes), a distinct pharmacological class - Although they form DNA cross-links (intrastrand and interstrand adducts) similar to alkylating agents, they do so via a different mechanism — **coordinate covalent bonding** with N7 of guanine, not through alkyl group transfer - Standard pharmacology references (KD Tripathi, Goodman & Gilman) list them separately from alkylating agents - Their dose-limiting toxicities (nephrotoxicity and ototoxicity for cisplatin) are correctly stated, but the **classification as alkylating agents is factually incorrect** - [cite: KD Tripathi Ch 65; Goodman & Gilman 13e Ch 61] **Key Point:** Platinum compounds are **NOT** alkylating agents. They are a separate class — platinum coordination complexes — that happen to share the mechanism of DNA cross-linking but differ in chemical mechanism and classification. **High-Yield:** | Drug Class | Examples | Dose-Limiting Toxicity | |---|---|---| | Classical Alkylating Agents | Cyclophosphamide, Ifosfamide, Melphalan, Busulfan | Myelosuppression; cystitis (cyclo/ifos) | | Platinum Compounds (separate class) | Cisplatin, Carboplatin, Oxaliplatin | Nephrotoxicity, ototoxicity (cisplatin); myelosuppression (carboplatin) | | Nitrosoureas | BCNU, CCNU | Myelosuppression, pulmonary fibrosis | **Clinical Pearl:** Cisplatin nephrotoxicity is prevented by aggressive IV hydration and amifostine. Carboplatin is less nephrotoxic but more myelosuppressive. Neither is classified as an alkylating agent in standard pharmacology texts. **Mnemonic: Platinum ≠ Alkylator** - Platinum compounds **cross-link** DNA but are **NOT** alkylating agents - They belong to their own class: **platinum coordination complexes**